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Background. Collaborative care is an eﬀective intervention for depression which includes both organizational and
patient-level intervention components. The eﬀect in the UK is unknown, as is whether cluster- or patient-randomization
would be the most appropriate design for a Phase III clinical trial.
Method. We undertook a Phase II patient-level randomized controlled trial in primary care, nested within a cluster-
randomized trial. Depressed participants were randomized to ‘collaborative care’ – case manager-coordinated medi-
cation support and brief psychological treatment, enhanced specialist and GP communication – or a usual care control.
The primary outcome was symptoms of depression (PHQ-9).
Results. We recruited 114 participants, 41 to the intervention group, 38 to the patient-randomized control group and 35
to the cluster-randomized control group. For the intervention compared to the cluster control the PHQ-9 eﬀect size was
0.63 (95% CI 0.18–1.07). There was evidence of substantial contamination between intervention and patient-randomized
control participants with less diﬀerence between the intervention group and patient-randomized control group (x2.99,
95% CI x7.56 to 1.58, p=0.186) than between the intervention and cluster-randomized control group (x4.64, 95% CI
x7.93 tox1.35, p=0.008). The intra-class correlation coeﬃcient for our primary outcome was 0.06 (95% CI 0.00–0.32).
Conclusions. Collaborative care is a potentially powerful organizational intervention for improving depression treat-
ment in UK primary care, the eﬀect of which is probably partly mediated through the organizational aspects of the
intervention. A large Phase III cluster-randomized trial is required to provide the most methodologically accurate test of
these initial encouraging ﬁndings.
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Introduction
Depression is a major health problem causing sub-
stantial disability and set to become the second largest
cause of global disability by 2020 (WHO, 2001). In the
UK depression and anxiety are estimated to cost the
economy £17bn in lost output with a £9bn impact on
the Exchequer through beneﬁt payments and lost tax
receipts (Layard, 2006). Only one in four depressed
people receive eﬀective pharmacological treatment
and less than 10% a talking therapy (Singleton et al.
2001). Bower & Gilbody (2005) have identiﬁed four
types of organizational strategies to improve this
situation : training and the use of guidelines for gen-
eral practitioners and primary care staﬀ; ‘consultation
liaison’, whereby specialist mental health practitioners
advise on the care of individual patients in primary
care ; ‘collaborative care’, an enhanced form of con-
sultation liaison which also includes a case manager to
deliver care and liaise between GP, specialist and
patient ; and ‘replacement referral ’ which refers to the
deployment of specialists in secondary or primary
care to whom GPs can refer.
A systematic review (Gilbody et al. 2003) of 36 such
organizational intervention studies concluded that
eﬀective strategies require complex interventions at the
‘systems level’, consisting of : (1) a multi-professional
approach to patient care ; (2) a structured patient
management plan; (3) scheduled patient follow-ups ;
and (4) enhanced inter-professional communication
(Wagner et al. 1996 ; Gunn et al. 2006). The most
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eﬀective systems-level intervention in this review was
‘collaborative care’ (Von Korﬀ & Goldberg, 2001 ;
Simon, 2006).
Although collaborative care improves outcomes
over usual care (Katon et al. 1999 ; Wells et al. 2000 ;
Unutzer et al. 2002), two recent systematic reviews
found small to medium mean eﬀect sizes of either
0.24 (95% CI 0.17–0.32) (Gilbody et al. 2006) or
0.40 (95% CI 0.20–0.60) (Gensichen et al. 2005). The
eﬀects associated with individual studies varied sig-
niﬁcantly, reﬂecting variation in the content of these
‘complex’ interventions (MRC, 2000). Further, most of
the studies originated from the USA (Gilbody et al.
2006).
Although there have been calls for the implemen-
tation of collaborative care in the UK (Simon, 2006),
these have not been supported by UK clinical guide-
lines (National Institute for Health and Clinical
Excellence, 2004) andmay be premature given that it is
not known exactly which models of collaborative care
work best, and whether the model will generalize to
the UK. In other areas of mental health such as
assertive community treatment (Killaspy et al. 2005),
the adoption of complex interventions based on inter-
national/US data before UK evaluation has resulted in
ineﬀective UK service developments.
We adopted the phased approach (Campbell et al.
2000) recommended by the Medical Research Council
(MRC) for investigating complex interventions
(MRC, 2000). We developed a UK-speciﬁc collabora-
tive care intervention for depression, based on analy-
sis of ‘active ingredients’ in published interventions
(Gilbody et al. 2006) and in-depth qualitative research
with stakeholders (Richards et al. 2006a). We then tes-
ted it in an exploratory Phase II randomized controlled
trial.
Cluster-randomized controlled trials are rec-
ommended for testing systems-level interventions
such as collaborative care (Ukoumunne et al. 1999),
since patient-randomized trials may be vulnerable
to contamination. Patients in the control group may
be inﬂuenced by system-level changes such as
advice from specialists and changes to the process
of care. Contamination in a patient-randomized trial
may result in underestimating the real eﬀect size of
collaborative care. However, cluster-randomized
trials require larger patient samples and often
greater resources. Our Phase II trial, therefore, used
an unusual design, nesting patient-level random-
ization within a cluster-randomized controlled trial
to investigate the presence and magnitude of con-
tamination (Fig. 1). We report the results of that
randomized controlled trial here, the ﬁrst UK trial
of collaborative care and an early test of the utility of
the MRC’s complex-interventions framework.
Ethical approval was given by the South West
Multi-site Research Ethics Committee.
Objectives
The objectives were :
(1) To estimate an eﬀect size for a UK-speciﬁc collab-
orative care protocol.
(2) To determine whether cluster or patient random-
ization would be the most appropriate design for a
Phase III trial.
Method
General practice sites were randomly allocated to
treatment or cluster control conditions from four
primary-care trusts (PCT) in the northern UK,
stratiﬁed by PCT. Almost all practices had a depri-
vation index higher than the UK national average and
a number were from areas where black and minority
ethnic groups were strongly represented. Patients in
the treatment cluster group were then individually
randomized to either collaborative care or usual
care control. Allocation was by a remote computer-
generated number sequence concealed from re-
searchers and conducted independently after patients
were enrolled in the study by research interviewers.
The randomization team at the trials unit informed
patients, GPs and, where appropriate, case managers,
of participant allocation. This created three study
groups (cluster-randomized controls, individually
randomized intervention patients, and individually
randomized control patients). Fig. 2 details the consort
diagram. To try to reduce the possibility of recruit-
ment bias GPs were given no information about the
allocation of their practice.
Sample
We recruited patients from primary care aged >18
years diagnosed as depressed by a GP, conﬁrmed by a
score ofo5 on the depression section of the Standard
Clinical Interview for DSM-IV (SCID; Spitzer et al.
1992) undertaken by trained research assistants. We
excluded patients with post-natal, bereavement or
physical causes for their depression. We only included
patients with a newly identiﬁed episode of major de-
pression, deﬁned as a current episode of GP-initiated
treatment of not more than 1 month’s duration. We
excluded patients reporting active suicidal plans and
those with a primary drug or alcohol dependence.
Although a standard power calculation based on de-
tecting treatment eﬀects would be the conventional
approach to determining the sample size for a clinical
trial, our Phase II study was designed to help inform
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the overall power calculation for a deﬁnitive Phase III
trial to be used together with estimates of the ‘expected
treatment eﬀect ’ (MRC, 2000) from published studies to
allow us to estimate a plausible eﬀect size for use in
the sample size calculation for the deﬁnitive Phase III
trial. Recruiting 32 patients in each of the patient-
randomized groups within the treatment cluster
would have given us a 95% conﬁdence interval width
of half an eﬀect size, allowing us to test for an eﬀect of
0.25 in either direction. Therefore, we aimed to recruit
The collaborative care intervention for depression consists of two aspects:
• A component A that impacts on the individual patient (e.g. medication management from the case manager).
• A component B that impacts on the general practice (e.g. feedback of patient information to the GP).
In a standard, individually randomized trial, component A only influences patients who are randomly allocated to
receive it, whereas component B may potentially influence all patients who are under the care of a particular
practice. Contamination occurs if the outcome of patients randomized to the control group is influenced by B, even
though those patients receive no benefit from A.
In the design adopted in this study, a patient level randomization study is nested within a cluster level randomized
study.
This has the advantage of allowing two analyses:
• The analysis of Group 1 versus Group 3 compares individually randomized intervention patients (who have
received the individual patient component A and the practice component B) with cluster-randomized control
patients (who have received neither A nor B). This analysis therefore provides the best overall indication of the
effect of the entire collaborative care intervention (i.e. A+B).
• The analysis of Group 2 versus Group 3 compares individually randomized control patients (who have received
the practice component B) with cluster-randomized control patients (who have received neither A nor B). This
analysis therefore provides the best overall indication of the effect of the practice component (i.e. B). As noted
above, this component B represents potential contamination in an individually randomised trial comparing
Group 1 and Group 2.
Group 1
Individually
randomized
intervention
patients
Receive A+B
Group 2
Individually
randomized
control patients
Receive B
Intervention
practices
Control
practices
Group 3
Cluster
randomized
control patients
Receive no
intervention
Cluster randomization of
practices
Individual
randomization of
patients
Fig. 1. Investigating contamination in a trial of a complex organizational intervention.
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Randomized (24 practices)
Excluded – 0
Refused to participate – 0
Allocated to intervention and patient randomized
cluster
(12 practices, mean 10740 patients,
range 2746–37000)
Allocated to usual care cluster control
(12 practices, mean 7042 patients,
range 1800–14000)
Lost to follow up
0 practices
Clusters analysed
(10 practices, mean 11751 patients, range 2746–37000)
Excluded from analysis
Practices with no referrals
(2 practices, mean 5687 patients, range 5000–6374) 
Participants
Participants followed up n=69 (87%)
Participants lost to follow up n=10 (could not be
contacted by researchers)
Intervention
Participants allocated
n=41
Participants received
intervention n=41
Usual care control
Participants allocated
n=38
Participants received usual
care n=38
Usual care control
Participants allocated n=35
Participants received usual care n=35
Assessed for eligibility (24 practices)
Intervention
participants
Participants analysed
n=35 (85%)
Participants not analysed
n=6 (lost to follow-up)
Patient randomized
control participants
Participants analysed
n=34 (90%)
Participants not analysed
n=4 (lost to follow-up)
Lost to follow up
0 practices
Clusters analysed
(9 practices, mean 7212 patients, range 1800–13500)
Excluded from analysis
Practices with no referrals
(3 practices, mean 6533 patients, range 2000–14000)
Participants
Participants followed up n=27 (77%)
Participants lost to follow up n=8 (could not be
contacted by researchers)
Cluster control participants
Participants analysed n=27 (77%)
Participants not analysed n=8 (lost to follow-up)
Participants randomized n=79
Assessed for eligibility n=137
Excluded n=58
Not depressed n=26
Not new episode n=20
Bereavement n=2
Declined n=8
Other n=2
Assessed for eligibility n=39
Excluded n=4
Not depressed n=1
Not new episode n=3
Fig. 2. Consort diagram.
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144 patients in total between the intervention and
control clusters, 32 of the extra patients compensating
for the design eﬀect, the remainder to account for any
attrition.
Intervention
Experimental
We developed a UK-speciﬁc collaborative care pro-
tocol in the modelling phase of our complex-
interventions trial (Gilbody et al. 2006 ; Richards et al.
2006a), which met the four criteria for an organiz-
ational, systems-level intervention (Wagner et al. 1996 ;
Gunn et al. 2006) : (1) a multi-professional approach to
patient care provided by a case manager working with
the GP under weekly telephone supervision from
specialist mental health medical and psychological
therapies clinicians ; (2) a structured management plan of
medication support and behavioural activation – a
structured cognitive-behaviourally based, depression-
speciﬁc psychological intervention which has equiv-
alent eﬃcacy to other more complex CBT inter-
ventions (Dimidjian et al. 2006 ; Cuijpers et al. 2007)
but is simpler to use and thus more suitable for col-
laborative care (Jacobson et al. 1996; Martell et al.
2001). No other interventions were permitted for the
duration of the trial ; (3) scheduled patient follow-ups via
a maximum of ten scheduled contacts over a period
of 3 months, predominantly using the telephone;
(4) enhanced inter-professional communication patient-
speciﬁc written feedback to GPs via electronic records
and personal contact. Case managers were a mix of
professionals (nurse, counsellor and occupational
therapist) and para-professionals (graduate primary-
care mental health workers) all of whom received
2 days of protocol-speciﬁc training in addition to their
existing clinical training and 30–45 min of supervision
per week for the duration of the trial.
Control
Usual care management of depression by patients’
GPs, including access to secondary services, and to
best practice guidance published in local NHS de-
pression protocols in the trial localities.
Outcome measures
The primary outcome was symptoms of depression
as measured by the Patient Health Questionnaire-9
(PHQ-9; Kroenke et al. 2001). Secondary outcomes
were the Clinical Outcomes in Routine Evaluation
– Outcome Measure (CORE-OM; Barkham et al. 2001),
measuring general wellbeing; the Short Form Health
Survey (SF-36 v.2 ; Ware et al. 2000), measuring health-
related quality of life. All assessments were completed
at baseline and 3 months post-randomization by
trained assessors blind to participant allocation.
Analysis
We aimed to determine a point estimate of the eﬀect
size of collaborative care, speciﬁc to the UK primary-
care setting. We conducted analysis of covariance ac-
counting for baseline imbalances in depression scores
and clustering within the units of randomization using
the Huber–White sandwich estimator (White, 1980)
within Stata 8 (Stata Corp., College Station, TX, USA).
We used an intention-to-treat approach to examine the
mean diﬀerences between the three groups and the
associated conﬁdence intervals and calculated coeﬃ-
cients to represent the diﬀerence between the cluster-
randomized controls and the intervention group in
follow-up outcome measures. For the main analysis of
the eﬀectiveness of the intervention, we calculated
the standardized eﬀect size (mean diﬀerence divided
by the pooled standard deviation) between the inter-
vention and cluster-randomized control groups. We
examined the degree of contamination by compar-
ing the coeﬃcients of individually randomized and
cluster-randomized control groups. We examined
clustering of outcomes within practices by calculating
the intra-class correlation coeﬃcient (ICC).
Results
We recruited 114 patients, 41 to the intervention
group, 38 to the patient randomized control group and
35 to the cluster-randomized control group (Fig. 2)
from February 2005 until March 2006. Table 1 details
the sample characteristics. The average number of case
manager/patient contacts was 6.46 (S.D.=1.69), taking
a mean time per patient of 191.13 min (S.D.=70.68).
We found an eﬀect size on PHQ-9 depression
symptoms of 0.63 (95% CI 0.18–1.07) for the inter-
vention compared to the cluster control (Table 2). We
found the intervention to be more eﬀective than the
cluster control on the CORE-OM (0.45, 95% CI
0.11–1.01) and the mental component score of the
SF-36 (0.67, 95% CI 0.19–1.16) but not more eﬀective
on the physical component score of the SF-36 (0.11,
95% CI x0.49 to 0.72). No adverse events were re-
ported in any group.
Evidence for substantial contamination was ob-
served, as there was less diﬀerence in PHQ-9 de-
pression outcomes between the intervention group
and patient-randomized control group (x2.99, 95% CI
x7.56 to 1.58, p=0.186) than between the intervention
group and cluster-randomized controls (coeﬃcient
x4.64, 95% CIx7.93 tox1.35, p=0.008). The ICC for
our primary outcome was 0.06 (95% CI 0.00–0.32).
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Discussion
We found a moderate to large eﬀect (Cohen, 1988 ;
Lipsey & Wilson, 2001) of collaborative care, an eﬀect
which would be considered clinically signiﬁcant
under the guidelines for depression produced by the
National Institute for Health and Clinical Excellence
(2004), the ﬁrst time this has been demonstrated in
the UK. This eﬀect is greater than that determined
by systematic reviews (Gensichen et al. 2005 ; Gilbody
et al. 2006) and equates to a mean diﬀerence between
treated and usual care patients of 5 points on the PHQ-
9. Five points is the diﬀerence between symptoms of
mild or moderate/severe intensity and between
symptoms of moderate/severe and severe intensity.
Furthermore, change in PHQ-9 scores achieved by the
intervention patients from baseline to follow-up
equates to a clinical shift of almost two categories of
depression severity.
The optimal design for a full Phase III trial has also
been clariﬁed by the phased approach. We detected
clear evidence of contamination, which has not always
been accounted for in previous collaborative care
studies (Gilbody et al. 2003). The individually
randomized controls were closer to the intervention
patients than to the cluster-randomized controls.
Although striking, the precise mechanism of the con-
tamination is unclear, but may relate to the sharing
of information between case manager and GP.
Examination of this mechanism may prove fruitful for
the further development of interventions. As in any
cluster-randomized trial, however, unmeasured dif-
ferences between doctors could also explain some
diﬀerences in outcomes, although we were careful to
stratify cluster randomization by our four clinical sites
to protect against this source of bias.
The main limitation of this study is the relatively
small numbers in what was a Phase II trial.
Table 1. Baseline characteristics of sample
Intervention
(n=41)
Patient-randomized
control (n=38)
Cluster-randomized
control (n=35)
Total
(n=114)
Gender
Female 32 (78%) 29 (76%) 27 (77%) 88 (77%)
Male 9 (22%) 9 (24%) 8 (23%) 26 (23%)
Age (yr)
Mean (S.D.) 42.63 (12.33) 43.00 (14.88) 41.71 (13.99) 42.47 (13.62)
Range 20–72 18–77 19–71 18–77
Ethnic origin
White British 38 (93%) 33 (87%) 27 (77%) 98 (86%)
Other 3 (7%) 5 (13%) 8 (23%) 16 (14%)
Education
None 9 (22%) 9 (24%) 10 (29%) 28 (25%)
GCSE/0 Level 11 (27%) 9 (24%) 13 (37%) 33 (29%)
Post-GCSE/0 level 16 (39%) 15 (39%) 9 (26%) 40 (35%)
Degree or higher 3 (7%) 4 (11%) 3 (9%) 10 (9%)
Other or ‘don’t know’ 2 (5%) 1 (3%) 0 3 (3%)
Employment status
Employed/self-employed 24 (59%) 14 (40%) 17 (49%) 56 (49%)
Not working 17 (41%) 24 (60%) 18 (51%) 58 (51%)
Marital status
Married/cohabiting 26 (63%) 25 (66%) 10 (29%) 61 (54%)
Baseline score means (S.D.)
PHQ-9 17.51 (4.90) 16.29 (4.47) 18.17 (5.58) 17.31 (5.00)
SCL-20 47.34 (12.15) 43.84 (12.38) 47.85 (14.60) 46.34 (13.02)
CORE-OM 2.02 (0.58) 1.88 (0.61) 2.12 (0.55) 2.00 (0.58)
SF-36 MCS 19.06 (11.42 20.33 (10.19) 18.64 (10.98) 19.36 (10.80)
SF-36 PCS 50.80 (10.88) 50.99 (11.05) 49.2 (14.18) 50.38 (11.94)
EQ5D 0.55 (0.26) 0.56 (0.30) 0.43 (0.32) 0.52 (0.29)
PHQ-9, Patient Health Questionnaire-9 ; SCL-20, Hopkins Symptoms Checklist Depression Scale ; CORE-OM, Clinical
Outcomes in Routine Evaluation – Outcome Measure ; SF-36 MCS, Short Form Health Survey mental component score ; SF-36
PCS, Short Form Health Survey physical component score ; EQ5D, EuroQuol 5 Dimension Scale.
284 D. A. Richards et al.
Consequently the results have wide conﬁdence
intervals around the mean and the eﬀect size we ob-
tained requires conﬁrmation in a full trial. Although
we did control for baseline depression severity as a
covariate in our analysis, small numbers also pre-
vented us balancing potentially important variables
such as ethnicity, marital status and gender in
our randomization which may or may not have in-
ﬂuenced our results. Further, although there were no
diﬀerences in consultations with GPs between
groups, we do not have full detailed information on
what constituted usual care in the control groups,
which may have varied substantially and aﬀected our
results. However, Phase II trials are an important
stage in carefully developing and testing new inter-
ventions and these results lend support to the utility
of the MRC’s complex-interventions research frame-
work (MRC, 2000), which provided a logical and
systematic structure to help us in the process of de-
signing and testing collaborative care in the UK. For
example, during our development work, we found
four previous UK studies of collaborative care which
in contrast to our results produced no or inconclusive
eﬀects (Wilkinson et al. 1993 ; Blanchard et al. 1995 ;
Mann et al. 1998 ; Peveler et al. 1999). These studies
were early trials in the development of collaborative
care, and had not used the systematic framework
to develop their interventions ; our review indicates
they had used suboptimal intervention ingredients
(Gilbody et al. 2006). Although the principle of care-
fully phased intervention development is an eﬀective
way to think about designing interventions and is
supported by our results, the framework is not pre-
scriptive and lacks close detail. Our speciﬁc approach
is only one of many methodological possibilities.
The research implications are that a fully powered
Phase III cluster-randomized trial should be the next
step of the MRC’s complex-interventions phased ap-
proach (Campbell et al. 2000 ; MRC, 2000) to in-
vestigating this complex intervention. Such a design
will provide the best protection against both over- and
underestimating the real eﬀect size of collaborative
care in the UK and will allow us to achieve a better
balance of baseline demographic characteristics. A
parallel qualitative investigation to this trial (Richards
et al. 2006b) has shown the clinical procedures to be
acceptable to patients, mental health workers and GPs.
If such a trial were to conﬁrm the eﬀect size of our
Phase II trial results, we will have evidence to enable
the NHS to substantially improve the organization of
its care for depressed patients in primary care and to
assist primary-care providers to deliver an eﬀective
Table 2. Follow-up scores, coeﬃcients of diﬀerence between intervention and patient-randomized control group with cluster controls,
95% CI and p values of the diﬀerence
Intervention
Patient-randomized
control
Cluster-randomized
control
PHQ-9 n=35 n=34 n=27
Mean (S.D.) 8.80 (7.02) 10.27 (7.51) 13.82 (8.32)
Coeﬃcient x4.64 x2.99 N.A.
95% CI x7.93 tox1.35 x7.56 to 1.58
p value 0.008 0.186
CORE-OM n=39 n=38 n=32
Mean (S.D.) 2.02 (0.58) 1.88 (0.61) 2.12 (0.55)
Coeﬃcient 0.34 x0.24 N.A.
95% CI x0.76 to 0.08 x0.69 to 0.20
p value 0.109 0.268
SF-36 MCS n=39 n=37 n=33
Mean (S.D.) 19.06 (11.42) 20.33 (10.19) 18.64 (10.98)
Coeﬃcient 9.89 2.95 N.A.
95% CI 2.79 to 17.00 x6.00 to 11.92
p value 0.009 0.497
SF-36 PCS n=39 n=37 n=33
Mean (S.D.) 50.80 (10.88) 50.99 (11.05) 49.2 (14.18)
Coeﬃcient 0.91 1.49 N.A.
95% CI x3.89 to 5.72 x3.02 to 6.00
p value 0.694 0.497
PHQ-9, Patient Health Questionnaire-9 ; CORE-OM, Clinical Outcomes in Routine Evaluation – Outcome Measure ; SF-36
MCS, Short Form Health Survey mental component score ; SF-36 PCS, Short Form Health Survey physical component score.
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model of enhanced depression service within the GP
contract.
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